Compare Heron Therapeutics Inc (HRTX) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Vertiv Holdings Co — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while Vertiv Holdings Co trades at $244.13 (market cap $93.83B). The key difference: Vertiv Holdings Co is far larger — about 1379.7× Heron Therapeutics Inc's market cap, and Vertiv Holdings Co pays a 0.1% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Vertiv Holdings Co for 39 Days on average.
| HRTX | VRT | |
|---|---|---|
Market Cap | $68.01M | $93.83B |
Volume | 1,891,941 | 5,855,911 |
Sector | Health | Industrials |
52-Week High | $1.49 | $376.23 |
52-Week Low | $0.27 | $149.83 |
Typical Hold Time | 35 Days | 39 Days |
Enterprise Value | $174.75M | $94.06B |
Dividend Yield | — | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Vertiv (VRT) trades at $246.49, down 2.63% on the day, as technical indicators show bearish momentum with the stock testing support near $242. Fundamentally, the company demonstrates strong profitability with 38% gross margins and 15% net income margins, while recent earnings have consistently beaten expectations. Revenue growth accelerated from $10.2B in 2025 to $11.5B projected for 2026, driven by AI data center demand.
The investment case balances strong analyst support (95% buy ratings with $364.94 price target) against elevated valuation multiples (P/E of 55) and recent legal scrutiny. While AI infrastructure tailwinds provide growth catalysts, the stock faces technical headwinds and needs to maintain its earnings beat streak to justify premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
